HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Byron, P. R. Search for Related Content PubMed PubMed Citation Articles by Byron, P. R.

Drug Delivery Devices

Issues in Drug Development

Virginia Commonwealth University, Richmond, Virginia

Correspondence and requests for reprints should be addressed to Peter R. Byron, Ph.D., Professor and Chairman, Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298-0533. E-mail: prbyron{at}vcu.edu

New techniques for delivery of drugs by inhalation are discussed in this article. Devices that promise to improve the efficiency of lung delivery are described along with some of the regulatory challenges faced by their development scientists. Although high delivery efficiencies are possible, such devices are expensive to develop and may only be feasible in the event that they are partnered with drugs whose therapeutic and economic value is truly enhanced by the effort invested in the process. Appropriate devices must also be selected after paying careful attention to the physicochemical and dosing demands associated with the drug substance to be inhaled. Even newly launched commercial products display large variations in dose delivery to the lung, in spite of increased global efforts to regulate and ensure the uniformity of delivered doses and their aerosol size distributions; this because of variations in the inspiratory maneuvers used by patients and the lack of control exercised over these maneuvers by most new inhalers. Sophisticated electromechanical techniques are discussed as possible ways of overcoming some of the common difficulties associated with ensuring reproducibility of dose and drug delivery to the lung.

Key Words: aerosol • drug • delivery devices • inhalers • lungs

This article has been cited by other articles:

				J. Xi, P. W. Longest, and T. B. Martonen Effects of the laryngeal jet on nano- and microparticle transport and deposition in an approximate model of the upper tracheobronchial airways J Appl Physiol, June 1, 2008; 104(6): 1761 - 1777. [Abstract] [Full Text] [PDF]

				S. P. Newman Inhaler treatment options in COPD Eur. Respir. Rev., December 1, 2005; 14(96): 102 - 108. [Abstract] [Full Text] [PDF]

				J. S. Patton, C. S. Fishburn, and J. G. Weers The Lungs as a Portal of Entry for Systemic Drug Delivery Proceedings of the ATS, December 1, 2004; 1(4): 338 - 344. [Abstract] [Full Text] [PDF]